Palvella Therapeutics, Inc. Common Stock (PVLA) is a publicly traded Healthcare sector company. As of May 21, 2026, PVLA trades at $115.50 with a market cap of $1.51B and a P/E ratio of -30.54. PVLA moved +5.56% today. Year to date, PVLA is +30.60%; over the trailing twelve months it is +397.20%. Its 52-week range spans $11.17 to $151.18. Analyst consensus is strong buy with an average price target of $231.00. Rallies surfaces PVLA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Palvella’s QTORIN Rapamycin Delivers +2.5-Point Bleeding Score Gain in Phase 2 Trial: Palvella Therapeutics reported that in its Phase 2 TOIVA trial, 100% of patients with bleeding at baseline (n=4) demonstrated a +2.5-point improvement on the cVM-IGA Bleeding scale at Week 12 (p=0.003). All such patients reported being “satisfied” or “very satisfied” with QTORIN rapamycin, highlighting strong patient-reported outcomes.
| Metric | Value |
|---|---|
| Price | $115.50 |
| Market Cap | $1.51B |
| P/E Ratio | -30.54 |
| EPS | $-3.71 |
| Dividend Yield | 0.00% |
| 52-Week High | $151.18 |
| 52-Week Low | $11.17 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $2.59M |
| Net Income | $-41.72M |
| Gross Margin | 0.00% |
14 analysts cover PVLA: 0 strong buy, 14 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $231.00.